

**REDX PHARMA PLC**  
**("Redx" or "the Company")**

**Appointment of Joint Broker**

**Alderley Park, 15 March 2021** Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside WG Partners with immediate effect.

**For further information, please contact:**

**Redx Pharma Plc**

**T: +44 1625 469  
918**

Iain Ross, Chairman  
Lisa Anson, Chief Executive  
James Mead, Chief Financial Officer

**SPARK Advisory Partners (Nominated Adviser)**

**T: +44 203 368  
3550**

Matt Davis/Adam Dawes

**WG Partners LLP (Joint Broker)**

**T: +44 20 3705  
9330**

Claes Spång/Chris Lee/David Wilson

**Panmure Gordon (UK) Limited (Joint Broker)**

**T: +44 20 7886  
2500**

Rupert Dearden/Freddy Crossley/Emma Earl

**FTI Consulting**

**T: +44 20 3727  
1000**

Simon Conway/Ciara Martin

**About Redx Pharma Plc**

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPDKQBBCBKDQND